Skip to main content

Simulations Plus, Inc.

corporate_fare Company Profile

Simulations Plus, Inc.

SLP·NASDAQ·Life Sciences·CIK 0001023459

Simulations Plus, Inc. is a global leader and premier provider in the biopharma sector, incorporated in California on July 17, 1996. The Company offers advanced software and consulting services that enhance drug discovery and development, clinical trial operations, and commercialization. Simulations Plus supports clients across the drug development lifecycle, from early discovery through all phases of clinical research and development (R&D), including clinical operations, to product commercialization. The Company serves clients as a strategic partner, offering solutions that integrate scientific software platforms, artificial intelligence-augmented insights, and expert consulting. Simulations Plus's model-informed drug development (MIDD) software and services solutions allow clients to use modeling and simulation to accelerate the drug development timeline, minimize animal testing, reduce R&D costs, comply with regulatory guidance and best practices, and increase confidence in drug safety and efficacy. The Company's clinical operations solutions support the success of clinical trials by enhancing participant diversity and retention, and driving competency and compliance with trial protocols. Additionally, its commercialization solutions provide support in obtaining regulatory approval and post-regulatory commercialization of new treatments. The Company's mission is to create value for clients by accelerating and reducing R&D costs through innovative science-based software and consulting solutions.

Simulations Plus, Inc. (NASDAQ:SLP) is a publicly traded company in the Life Sciences sector. Wiseek monitors SLP SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Simulations Plus Faces Securities Probe Over $77.2M Impairment, Auditor Dismissal
  • Simulations Plus Reports Strong Q2 Net Income & Operational Efficiency, Boosts R&D Investment
  • Simulations Plus Reports Strong Q2, Cuts Full-Year EPS Guidance by ~25% Due to Higher Tax Rate
  • Simulations Plus Reports Q2 EPS of 22 Cents
  • Shareholders Approve Significant Increase in Equity Incentive Plan Shares

Financial Snapshot

Fiscal year ended August 31, 2025
Revenue
$79.18M
Net Income
-$64.72M
Diluted EPS
-$3.22
Op. Cash Flow
$18.13M
Free Cash Flow
$17.41M
Gross Profit
$46.22M
Operating Income
-$70.73M
Cash & Equivalents
$30.85M
Debt / Equity
0.00×
Net Margin
-81.7%
Shares Outstanding
20.14M sh
Source: 10-K · filed 2025-12-01 · accession 0001023459-25-000060
Browse all tickers starting with S →
$16.32
52-week range · as of 2026-04-10 $11.09 – $36.45
Market cap
$329.75M
Volume
160.7K (0.5× avg)
3-mo avg 312.7K
Live data · 2026-06-14 03:51 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SLP - Latest Insights

SLP
Jun 08, 2026, 8:17 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $15.88
Real-time Price: $16.32 info
Change: +$0.440 (+3%) info
Market Cap: $329.753M info
SLP
Apr 10, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $13.04
Real-time Price: $16.32 info
Change: +$3.28 (+25%) info
Market Cap: $329.753M info
SLP
Apr 09, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.00
Real-time Price: $16.32 info
Change: +$1.32 (+9%) info
Market Cap: $329.753M info
SLP
Apr 09, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $14.28
Real-time Price: $16.32 info
Change: +$2.04 (+14%) info
Market Cap: $329.753M info
SLP
Feb 18, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.18
Real-time Price: $16.32 info
Change: +$4.14 (+34%) info
Market Cap: $329.753M info
SLP
Jan 09, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $19.55
Real-time Price: $16.32 info
Change: -$3.23 (-17%) info
Market Cap: $329.753M info